Archived M184V/I Mutation and Risk of Virological Failure After Switching to Doravirine, Lamivudine, Tenofovir Disoproxil Fumarate: A National Observational Study (Dat’AIDS Cohort)

Clicks: 1
ID: 319592
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #194 of 208 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 208 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Among 1,282 virally suppressed people with HIV switching to doravirine/lamivudine/tenofovir disoproxil fumarate, 40 (3.1%) experienced virological failure (VF) during follow-up (median 81 weeks). Archived M184V/I mutation (7.4% of study population) was not significantly associated with VF after adjustment (adjusted hazard ratio 1.36; 95%CI 0.51-3.66).
Reference Key
openalex_W7167269160 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Romain Palich, Axel Ursenbach, Nolwenn Hall, A Becker, Clotilde Allavena, Olivier Robineau, Laurent Hocqueloux, the Dat’AIDS Study Group, C Chirouze, K Bouiller, F Bozon, A S Brunel, L Hustache-Mathieu, J Lagoutte, Q Lepiller, S Marty-Quinternet, L Pépin-Puget, B Rosolen, N Tissot, C Lebreton, L Bohard, S Jaffuel, S Ansart, Y Quintric, S Rezig, L Quaesaet, P Gazeau, C Goujard, A Castro-Gordon, P David-Chevallier, V Godard, Y Quertainmont, E Teicher, S Jaureguiberry, L Escaut, M Cresta, B Henry, E Oliosi, C Couzigou, O Derradji, R Collarino, Y Liotier, M Merad, E Zamparini, J Bottero, V Joly, C Charpentier, D Descamps, M Digumber, A Gervais, J Ghosn, Z Julia, R Landman, S Lariven, S Le Gac, F Louni, N Peiffer-Smadja, G Peytavin, C Rioux, Y Yazdanpanah, L Deconinck, C Jacomet, N Mrozek, C Theis, M Vidal, C Richaud, V Corbin, A Benelhadj, A Zaghdoudi, C Aumeran, O Baud, M Berthommier, M Charles, C Durand, D Coban, A Mirand, A Brebion, H Chabrolles, O Perruche, E Creuzet, C Henquell, I Lamaury, G Baronnet, F Bissuel, F Boulard, A Chéret, J Coussement, E Curlier, T Dequidt, C Desfontaines, S Devatine, E Duvallon, I Fabre, C Herrmann-Storck, C Loraux, S Markowicz, M Marquet, R Ouissa, S Peugny, L Pradat-Paz
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag399
URL
https://doi.org/10.1093/ofid/ofag399
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.